Table I.
Baseline characteristics.
| Characteristic | N (%) |
|---|---|
| Follow-up period (months)a | 21.0 (5.1-73.4) |
| Age (years)a | 66 (37-84) |
| Sex | |
| Male | 53 (74.6) |
| Female | 18 (25.4) |
| Performance score (ECOG) | |
| 0 | 57 (80.3) |
| 1 | 15 (18.3) |
| 2 | 1 (1.4) |
| Tumor location | |
| Right | 22 (31.0) |
| Left | 49 (69.0) |
| Colon/rectum | |
| Colon | 44 (62.0) |
| Rectum | 27 (38.0) |
| Primary lesion removal before chemotherapy | |
| Yes | 48 (67.6) |
| No | 23 (32.4) |
| Adjuvant chemotherapy | |
| Yes | 27 (33.8) |
| No | 47 (66.2) |
| Indication for chemotherapy | |
| Unresectable primary lesion | 3 (4.2) |
| Unresectable local recurrence | 4 (5.6) |
| Distant metastasis | 66 (93.0) |
| Synchronous/metachronous metastasis | |
| Synchronous | 40 (56.3) |
| Metachronous | 29 (40.8) |
| Metastasis sites | |
| Liver | 38 (53.5) |
| Lung | 31 (43.7) |
| Lymph node | 17 (23.9) |
| Peritoneum/local | 14 (19.7) |
| Number of metastasis sites | |
| 0 | 2 (2.8) |
| 1 | 39 (54.9) |
| ≥2 | 30 (42.2) |
| Histology | |
| Differentiated | 67 (94.4) |
| Non-differentiated | 4 (5.6) |
| RAS gene status | |
| Wild | 31 (43.7) |
| Mutant | 31 (43.7) |
| Unknown | 9 (12.7) |
aData are presented as the median (range). ECOG, Eastern Cooperative Oncology Group.